If you are an investor and want to take part in the future of biomedical data, now is the time to get to know BIOINFILE.
BIOINFILE is a bioinformatics startup (also known as part of the “Golden Biotechnology”) that has developed a pioneering Data as a Service (DaaS) platform specialized in biomedical data.
Its value proposition focuses on offering expertly curated, ready-to-use datasets tailored to specific use cases in biomedicine. In doing so, it solves one of the sector’s main bottlenecks: access to reliable data for validating diagnostic and therapeutic developments.
BIOINFILE is part of Lanzadera, the leading Spanish accelerator, and has secured over €129,000 in public grants to develop its proprietary Data Space infrastructure. The company is now raising a €150,000 pre-seed round to strengthen its technical and commercial teams, expand its data portfolio, and launch an automated API for seamless access to its services by 2027.
